Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib

Front Immunol. 2024 Nov 26:15:1527232. doi: 10.3389/fimmu.2024.1527232. eCollection 2024.

Chenghao Fu^#^{1

2}, Haonan Du^#¹, Qiang Wang^#³, Weiyou Zhu¹, Guangli Bian⁴, Zhujuan Zhong⁵, Yuheng Wang², Lei Cao⁶

¹ Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
² Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
³ Department of Thoracic Surgery, Taizhou Fourth People's Hospital, Taizhou, Jiangsu, China.
⁴ Department of Radiology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.
⁵ Department of Pathology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.
⁶ Department of Oncology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2024.1452195.].

Keywords: ICI; PSC; Sintilimab; cancer therapy; immunotherapy; tail effect.